584 related articles for article (PubMed ID: 15920337)
41. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
Dodick D; Brandes J; Elkind A; Mathew N; Rodichok L
CNS Drugs; 2005; 19(2):125-36. PubMed ID: 15697326
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and tolerability of almotriptan in postmarketing surveillance studies.
Pascual J
Eur Neurol; 2005; 53 Suppl 1():34-40. PubMed ID: 15920336
[TBL] [Abstract][Full Text] [Related]
43. Use of almotriptan in triptan-experienced and triptan-naïve patients.
Pascual J; Diener HC
Curr Med Res Opin; 2007 Oct; 23(10):2433-40. PubMed ID: 17723158
[TBL] [Abstract][Full Text] [Related]
44. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).
Freitag FG; Finlayson G; Rapoport AM; Elkind AH; Diamond ML; Unger JR; Fisher AC; Armstrong RB; Hulihan JF; Greenberg SJ;
Headache; 2007 Apr; 47(4):519-30. PubMed ID: 17445101
[TBL] [Abstract][Full Text] [Related]
45. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine.
Chen LC; Ashcroft DM
Headache; 2008 Feb; 48(2):236-47. PubMed ID: 18179569
[TBL] [Abstract][Full Text] [Related]
46. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial.
Schulman EA; Cady RK; Henry D; Batenhorst AS; Putnam DG; Watson CB; O'Quinn SO
Mayo Clin Proc; 2000 Aug; 75(8):782-9. PubMed ID: 10943230
[TBL] [Abstract][Full Text] [Related]
47. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine.
Goldstein J; Smith TR; Pugach N; Griesser J; Sebree T; Pierce M
Headache; 2012 Oct; 52(9):1402-10. PubMed ID: 22694484
[TBL] [Abstract][Full Text] [Related]
48. A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point.
Williams P; Reeder CE
J Manag Care Pharm; 2004; 10(3):259-65. PubMed ID: 15228377
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group.
Bousser MG; D'Allens H; Richard A
J Intern Med; 1993 Aug; 234(2):211-6. PubMed ID: 8393474
[TBL] [Abstract][Full Text] [Related]
50. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials.
Winner P; Landy S; Richardson M; Ames M
Clin Ther; 2005 Nov; 27(11):1785-94. PubMed ID: 16368449
[TBL] [Abstract][Full Text] [Related]
51. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168
[TBL] [Abstract][Full Text] [Related]
52. Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice.
Diener HC
Headache; 2005 Jun; 45(6):624-31. PubMed ID: 15953293
[TBL] [Abstract][Full Text] [Related]
53. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea.
Schulman EA
Headache; 2012 Feb; 52(2):204-12. PubMed ID: 22229837
[TBL] [Abstract][Full Text] [Related]
54. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study.
Pascual J; Falk RM; Piessens F; Prusinski A; Docekal P; Robert M; Ferrer P; Luria X; Segarra R; Zayas JM
Cephalalgia; 2000 Jul; 20(6):588-96. PubMed ID: 11075844
[TBL] [Abstract][Full Text] [Related]
55. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan.
Goadsby PJ; Zanchin G; Geraud G; de Klippel N; Diaz-Insa S; Gobel H; Cunha L; Ivanoff N; Falques M; Fortea J
Cephalalgia; 2008 Apr; 28(4):383-91. PubMed ID: 18294251
[TBL] [Abstract][Full Text] [Related]
56. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design.
Geraud G; Olesen J; Pfaffenrath V; Tfelt-Hansen P; Zupping R; Diener HC; Sweet R
Cephalalgia; 2000 Feb; 20(1):30-8. PubMed ID: 10817444
[TBL] [Abstract][Full Text] [Related]
57. Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis.
Seeburger JL; Cady RK; Winner P; MacGregor A; Valade D; Ge Y; Zhang Y; Hustad CM; Strickler N; Schaefer E; Connor KM; Ho TW
Headache; 2012 Jan; 52(1):57-67. PubMed ID: 22078129
[TBL] [Abstract][Full Text] [Related]
58. A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. Sumatriptan Tablets S2CM07 Study Group.
Savani N; Brautaset NJ; Reunanen M; Szirmai I; Ashford EA; Hassani H; Saiers J
Int J Clin Pract Suppl; 1999 Aug; 105():7-15. PubMed ID: 10692717
[TBL] [Abstract][Full Text] [Related]
59. Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan.
Díez FI; Straube A; Zanchin G
J Neurol; 2007 Feb; 254(2):242-9. PubMed ID: 17334957
[TBL] [Abstract][Full Text] [Related]
60. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials.
Dahlöf CG; Pascual J; Dodick DW; Dowson AJ
Cephalalgia; 2006 Apr; 26(4):400-8. PubMed ID: 16556240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
